William G. Wierda, MD, PhD, on Clinical Implications of Experimental CAR T-Cell Treatment in Relapsed/Refractory CLL/SLL

Posted: Thursday, August 1, 2019

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses study findings on the ability of a CD19-directed CAR T-cell therapy to eradicate minimal residual disease in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.